This is the second volume of the comprehensive, two-volume work on oxidative stress in lung diseases. Adopting a multidisciplinary approach, it demonstrates the cellular and molecular mechanisms associated with ROS (reactive oxygen species)-induced initiation and progression of a variety of lung diseases, such as COPD, emphysema, asthma, cystic fibrosis, occupational pulmonary diseases and pulmonary hypertension and discusses points for therapeutic intervention. The book also covers translational research and the latest research on prevention and therapeutics. Each chapter includes in-depth insights into the mechanisms associated with lung diseases and into identifying targets for drug development. Bridging the gap between fundamental and translational research, and examining applications in the biomedical and pharmaceutical industry, it is a thought- provoking read for basic and applied scientists engaged in biomedical research.

A.  General Aspects of reactive oxygen species-mediated lung diseases

1.  “Pathology of lung diseases affected by oxidative stress”

 2. “Approach of smoke-related lung damage” 

 3. “The state of art of NADPH Oxidase-dependent oxidative stress in lung diseases” 

 4. “Effects of radicals on pulmonary surfactant and role of lipid in this scenario”

 5. “Infection induced oxidation and DNA repair”

 6. “Oxidative stress in experimental models of acute lung injury” 
 7. “Oxidative Lipidomics of Lung Diseases”

 

 B.  Chronic lung diseases

 8. “Oxidative stress in Lung Fibrosis”

9. “Oxidative Stress Biomarkers in COPD”

10. “Oxidative stress in emphysema”

11. “Oxidative stress induced mitochondrial dysfunction and asthma”

12. “Oxidative stress in asthma and COPD” 

 

 D. Other lung diseases

13. “Oxidative stress in environmental lung diseases”

 14. “Bronchopulmonary dysplasia and oxidative stress in preterm newborns”

 15. “Effect of exogeneous chemical exposure on oxidative stress induced lung diseases”

 16. “Pulmonary antioxidant system in acute and chronic lung injury, pulmonary fibrosis in diabetes”

 17.“Mitochondrial alterations and oxidative stress in cystic fibrosis”

 

 E. Prevention and therapeutics

18. “Flagellin/Toll-like receptor 5 response was specifically attenuated by keratin sulfate disaccharide via decreased EGFR phosphorylation in human bronchial epithelial cells”

19. “Therapeutic targeting of oxidative stress and inflammation in COPD and asthma: Pharmacological intervention with phytochemicals”

20. “ROS: modulator of therapeutic response in non-small cell lung cancer (NSCLC)”

21. “Arsenic-induced lung injury in rats and its reversal by a garlic polysulfide” 

22. “The Mitochondria-targeted Drugs for Protection of Lung Damage and Pulmonary Diseases”.

23. “The use of ozone as redox modulator in the treatment of chronic pulmonary disease (COPD)”

24. “Oxidative stress and therapeutic development in lung cancer”

25.The state of art of NADPH Oxidase-dependent oxidative stress in lung diseases.

26.   Pharmacological modulation of  ROS impairs the airway hyper responsiveness by shifting the Th1 response in allergic inflammation induced by ovalbumin

27.   Flagellin/Toll-like receptor 5 response was specifically attenuated by keratin sulfate disaccharide via decreased EGFR phosphorylation in human bronchial epithelial cells.

28.  Oxidative stress in experimental models of acute lung injury.

 29. Pharmacokinetics, pharmacodynamics and safety of ISO1957, a preclinical candidate possessing activity against infection.

30. Rho kinase as a therapeutic target in pulmonary vascular diseases.

31. Mesenchymal stromal cell injection protects against oxidative stress in E.coli induced lung injury in mice.

32.  Phosgene induced lung damage and its amelioration by cAMP elevating compounds.